RECURRENT PROSTATE CANCER

This early-phase trial tests whether an experimental DNA vaccine (pTVG-HP) combined with the immunotherapy drug nivolumab and targeted radiation can help the immune system attack prostate cancer that has returned in a few spots. The study involves 14 men whose cancer has come bac…

This study tests a high-dose radiation implant (brachytherapy) for men whose prostate cancer returned after standard external beam radiation. About 30 participants will receive this targeted treatment to the exact spot of recurrence, identified by advanced MRI. The goal is to con…

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This study tests a treatment that uses lasers and a light-sensitive drug to destroy cancer cells in the prostate without major surgery. It is for men whose prostate cancer has returned after radiation therapy and who cannot have surgery or more radiation. The goal is to see if th…

This study looks at the best timing for combining targeted radiation (SBRT) with hormone therapy in men whose prostate cancer has returned and spread. It also tests if radiation to the pelvis can stop cancer from spreading further. About 532 men with recurrent, hormone-sensitive …

This study tests whether using a special PET scan (PSMA-PET) to guide radiation can reduce short-term side effects in men whose prostate cancer returns after surgery. About 54 men will receive targeted radiation to the pelvis plus a boost to spots seen on the scan, along with sta…

This study for veterans with prostate cancer that has returned in a few spots (oligorecurrence) compares standard systemic therapy alone versus standard therapy plus PET-directed local treatment using surgery or radiation. The goal is to see if adding local therapy delays the can…

This phase II trial is testing whether terbinafine, a widely used antifungal pill, can slow the rise of PSA in men whose prostate cancer has returned after initial treatment. The goal is to see if this well-tolerated drug can delay or replace standard hormone therapy, which often…

This study is collecting prostate cancer tissue from 16 men with metastatic prostate cancer to analyze the tumor microenvironment—the cells and structures around the tumor. Researchers will use advanced genetic and molecular tests to understand how the immune system interacts wit…

This study aims to improve treatment for aggressive prostate cancer by growing 3D mini-tumors from patient samples in the lab. Researchers will compare two techniques to see which better predicts how a patient's cancer will respond to radiation or drugs. The goal is to help docto…

This study looks at 60 men with prostate cancer who had a high-risk genetic test (Decipher score >0.45). They will get a special PSMA-PET scan two years after their initial treatment to see if the cancer has spread. The goal is to learn how well the genetic test predicts early me…